2.5 Oncology, Immunology & Specialty Pharmacy

Oncology, Immunology & Specialty Pharmacy

Specialty pharmacy represents the most rapidly growing and highest-cost sector of healthcare. It encompasses the management of complex, chronic, and rare diseases, including oncology, solid organ transplant, and autoimmune disorders. These medications often require special handling, stringent cold chain management, complex REMS (Risk Evaluation and Mitigation Strategy) programs, and extensive patient education. A core competency for CPJE candidates is understanding supportive care in oncology, managing the profound drug interactions associated with immunosuppressants, and navigating the evolving legal landscape of biologics and biosimilars.

1. Oncology Supportive Care

Chemotherapy often involves narrow-therapeutic-index drugs that target rapidly dividing cells, leading to severe collateral damage to the bone marrow, gastrointestinal tract, and hair follicles. Managing these toxicities is as critical as the chemotherapy itself.

Chemotherapy-Induced Nausea and Vomiting (CINV)

CINV is one of the most feared side effects of cancer treatment. Emesis is driven by multiple neurotransmitters, primarily serotonin (5-HT3), dopamine, and Substance P (NK1). Anti-emetic regimens are initiated prior to chemotherapy based on the emetogenic potential of the regimen.

• High Emetic Risk (e.g., Cisplatin, Anthracyclines): Requires a 3- or 4-drug regimen. Standard consists of an NK1 Receptor Antagonist (Aprepitant), a 5-HT3 Receptor Antagonist (Ondansetron or Palonosetron), Dexamethasone, and often Olanzapine.
• Moderate Emetic Risk: Generally requires a 2- or 3-drug regimen (5-HT3 RA + Dexamethasone ± NK1 RA).
• Breakthrough CINV: Treated with different classes, such as dopamine antagonists (prochlorperazine, promethazine, metoclopramide) or cannabinoids (dronabinol). Note that dopamine antagonists can cause extrapyramidal symptoms (EPS) and lower the seizure threshold.

Unique Chemotherapy Toxicities and Antidotes

Certain chemotherapeutic agents cause specific, irreversible organ damage unless a targeted chemoprotectant or antidote is administered concurrently or shortly after.

2. Immunology and Solid Organ Transplant

Solid organ transplant recipients must remain on lifelong immunosuppression to prevent allograft rejection. The cornerstone of most maintenance regimens is a calcineurin inhibitor (CNI), combined with an antiproliferative agent and often corticosteroids.

Calcineurin Inhibitors (Tacrolimus and Cyclosporine)

CNIs block T-cell activation by inhibiting calcineurin, preventing the production of Interleukin-2 (IL-2).

• Tacrolimus (Prograf) is generally preferred over cyclosporine due to better efficacy and a more favorable side-effect profile, though it is highly diabetogenic and causes significant neurotoxicity (tremors) and nephrotoxicity.
• Cyclosporine (Neoral, Gengraf, Sandimmune) causes severe gingival hyperplasia, hirsutism, and nephrotoxicity.
  • Critical Note: Modified cyclosporine (Neoral, Gengraf) has a much greater bioavailability than non-modified (Sandimmune). They cannot be interchanged without strict physician oversight.

Pharmacokinetics and Monitoring: Both drugs have extremely narrow therapeutic indices and require routine trough level monitoring. Blood must be drawn immediately before the next scheduled dose. They are both major substrates of CYP3A4 and P-glycoprotein. Co-administration with strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, clarithromycin, grapefruit juice) will cause a massive spike in CNI levels, leading to acute renal failure. Conversely, CYP3A4 inducers (e.g., rifampin, St. John's Wort) will plummet levels, leading to rapid organ rejection.

3. Biologics and Biosimilars (California Law)

Biologic medications are large, highly complex molecules manufactured in living cells. Because they are so complex, identical generic versions cannot be created; instead, manufacturers create "biosimilars." A biosimilar is highly similar to the reference biological product with no clinically meaningful differences in terms of safety, purity, and potency.

The Purple Book and Interchangeability

The FDA publishes the Purple Book, which lists licensed biological products along with any highly similar or interchangeable biosimilar evaluations. Not all biosimilars are "interchangeable." To be legally interchangeable at the pharmacy level, the FDA must grant a specific "Interchangeable" designation, proving that switching back and forth does not increase safety risks or diminish efficacy.

California Business and Professions Code § 4073.5

California law strictly dictates how pharmacists handle biosimilar substitution:

1. The pharmacist may substitute a biological product with an alternative only if the FDA has explicitly determined the alternative to be "interchangeable."
2. The prescriber must not have indicated "Do Not Substitute" or "Dispense as Written."
3. Prescriber Notification: If a substitution is made, the pharmacist or pharmacy must communicate to the prescriber the specific product provided (including the name and manufacturer) within 5 business days of dispensing. This is usually done through an interoperable electronic medical records system, but can be done via fax or phone if necessary.
4. The patient must also be notified of the substitution.

Understanding these laws is critical, as specialty biologics (like Humira, Enbrel, Remicade) represent massive financial expenditures, and proper substitution ensures patient access while maintaining strict clinical safety parameters.